Develops experimental medicines for autoimmune diseases and cancer, including blood and lung cancers.
10-K for FY2025, filed Mar 10, 2026We are a biopharmaceutical company developing potential first- or best-in-class, high-impact therapies for autoimmune diseases and cancer.…View ↗
CLN-049 is a FLT3xCD3 bispecific T cell engager. CLN-049 is being evaluated in an ongoing Phase 1 clinical trial in patients with…View ↗
Zipalertinib (CLN-081/TAS6417), on which we are collaborating with an affiliate of Taiho Pharmaceutical Co., Ltd. ("Taiho"), is an…View ↗
10-Q for Q3 FY2026, filed Nov 10, 2026
−$49.4MView ↗
Broader disease focus
The older reports center on targeted cancer drug development across different treatment approaches; the latest report also focuses on autoimmune diseases and places T cell engagers at the center of its strategy.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Mar 10, 2026
The program's treatment focus
The program was initially aimed at relapsed B-cell non-Hodgkin lymphoma; the latest report says development there was discontinued and the candidate is being developed exclusively for autoimmune diseases.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Mar 10, 2026CLN-978 is a CD19/CD3 T cell engaging antibody construct with a human serum albumin ("HSA") binding domain to increase serum half-life. In…View ↗
Three patients were treated in a Phase 1 dose escalation trial in patients with relapsed/refractory B-NHL. At the initial starting dose of…View ↗
Competes with Amgen, Roche Holdings, AstraZeneca, Merck &, Novartis, GSK, Xencor, Zenas BioPharma, Eli Lilly and, Climb Bio, Regeneron Pharmaceuticals, Candid Therapeutics, Ouro Medicines, Astellas Pharma, Daiichi Sankyo, Aptose Biosciences, Veraxa Biotech, Hemogenyx Pharmaceuticals, Senti Biosciences, and Aptevo Therapeutics
10-K for FY2025, filed Mar 10, 2026With respect to our CLN-978 program, we are aware of multiple companies with development-stage CD19 T cell engager programs for the…View ↗
Loading...